India's Hetero to produce cancer and AIDS drugs in Russia

7 July 2017

Indian generic drugmaker Hetero Labs has announced plans to build a plant for the production of drugs against cancer and AIDS in Russia.

It is reported that the new facility will be located in the Tula region, a region in Central Russia, which is located in close proximity to Moscow, according to The Pharma Letter’s local correspondent.

The value of investments in the project may reach $30-$40 million. The exact range of drugs that will be produced by the new plant is not disclosed. It is planned that the majority of its future production will be supplied to the domestic market, where the demand for drugs against cancer and AIDS among local population has increased significantly in recent years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK